Chordate Medical has signed an agreement with Kalqyl for report monitoring and commissioned analyses. The collaboration includes independent monitoring of the company and its market potential with a valuation scenario from a potential buyer’s perspective.
“Our ambition is for shareholders and stakeholders to have access to a relevant analysis of the company and the market potential that aligns with the company’s strategy. Kalqyl’s previous work demonstrates a deep understanding of the market and well-founded analyses of listed companies,” says Anders Weilandt, CEO of Chordate Medical.
“Chordate is an exciting company. Starting from the perspective of a potential buyer of the company is a new way for us to do a company analysis, but at the same time, the most logical starting point,” says David Uhrner, CEO of Kalqyl.
About Kalqyl
Kalqyl is an analysis company with a rapidly growing platform and a unique reach among Nordic investors. Kalqyl’s analyses help companies clarify their business concepts and enable investors to better understand their operations. Kalqyl is a wholly owned subsidiary of Spotlight Group, acquired in August 2021.
